PR Newswire: nyheter distribution, inriktning och uppföljning

'The Contract Vaccine Manufacturing Market Will Reach $0.62 Billion in 2015' Predicts New Visiongain Report

Share with Twitter Share with LinkedIn

LONDON, January 22, 2013 /PRNewswire/ --

A new report by visiongain predicts that the world market for vaccines will reach $48bn in 2015. From this market, vaccine contract manufacturing will reach $0.62bn in 2015. Those forecasts and others appear in Vaccine Manufacturing Technology and Services: World Market 2013-2023, published in January 2013. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the vaccine manufacturing market will achieve strong growth from 2013 to 2023. Vaccine manufacturing is an area currently undergoing rapid development, driven by increasing demand from expanding populations and advances in technology. Rapid advances in biotechnology, immunology and genetics are a constant driving force behind the development of vaccines. In the future, vaccine development will increasingly concentrate on new classes of vaccine designed using recombinant DNA technology, instead of more traditional live, attenuated and inactivated viruses. In addition, use of such technology will allow vaccines to be developed for new diseases. Novel therapeutic vaccines, targeting diseases such as cancer, will be a high growth segment for this market to 2023. The emerging markets in India and China will also become important hubs for vaccine production, driven by healthcare demand in those regions.

Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "The vaccine manufacturing market is highly consolidated, with a few leading players dominating the market. Vaccine development and manufacturing is an expensive process, resulting in high entry barriers. However, there will be opportunities to enter this growing market. As pharma and biotech R&D budgets continue to tighten, companies will try to meet healthcare needs through manufacturing processes at lower cost and with improved efficiency. Outsourcing vaccine manufacturing is one solution - having the advantage of flexibility, whereby a company does not have to heavily invest in facilities, equipment and expertise, so it can focus its resources on other areas, such as marketing and R&D. There are many opportunities for contract pharma manufacturing organisations (CMOs), we note.

"Vaccine manufacturing will be driven by advances in technology and the growing vaccine market. There will be a drive towards cell based production methods, ultimately increasing productivity and efficiency. As vaccine manufacturing methods become more complex, the time consuming changeover of vaccine production lines will become ever more frequent. Single-use technologies, such as bioreactors, will benefit production methods. In addition, outsourcing of vaccine manufacturing offers a platform whereby companies can reduce costs and improve their vaccine production processes through outside expertise and flexibility. However, while the benefits of outsourcing are clear, there will be strong competition from in-house operations."

Visiongain's report provides revenue forecasts to 2023 at world market, submarket and national level. It forecasts world sales for the following submarkets:

• Paediatric vaccines
• Influenza vaccines
• Adult prophylactic vaccines
• Therapeutic vaccines
• Contract vaccine manufacturing.

That investigation also analyses 14 leading companies including GSK, Pfizer, Novartis, Charles River Laboratories, Baxter BioPharma Solutions, Catalent and Lonza.

The analysis includes researching trends and forecasting revenues in leading national markets. Countries and regions analysed are the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC nations). Within the analyses, opportunities and developments are discussed.

Vaccine Manufacturing Technology and Services: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For further information concerning the Visiongain's Vaccine Manufacturing Technology and Services: World Market 2013-2023 report please visit http://www.visiongain.com/Report/966/Vaccine-Manufacturing-Technology-and-Services-World-Market-2013-2023

Contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Companies Listed

AAI Pharma Services
Acambis
Accugenix
ACIP (Advisory Committee on Immunization Practices)
Advanced Bioscience Laboratories
Aeras Global
AfriVax
Alpha Biologics
Althea Technologies
Amgen
AmProtein
Angel Biotechnology Holdings
Antigenics
ANVISA (National Health Surveillance Agency) Brazil
Aptuit
Artelis
AstraZeneca
ATMI LifeSciences
AVEO Pharmaceuticals
Bacteriological Institute of the Anhaltian Administrative Areas
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer
Bayer Schering Pharma AG
Ben Venue Laboratories
Berna Biotech
Bharat Biotech International
Biken Japan
Bill and Melinda Gates Foundation
Binnopharm
Bioline
Biological E
Bio-Manguinhos
Biomay
Biomedical Advanced Research and Development Authority (BARDA)
Biovian
BioXcellence
Blackstone Group
Boehringer Ingelheim
Butantan
Cardinal Health
Catalent
Catalent Pharma Solutions
CDC (Centers for Disease Control and Prevention) US
Cellexus
Charles River Laboratories
Chemo-Sero-Therapeutic Research Institute
China National Biotec Group (CNBG)
Chiron
CHMP (The Committee for Medicinal Products for Human Use) Europe
Cook Pharmica
Crucell
CSL Behring
CSL Biotherapies
Cytovance Biologics
Daiichi Sankyo
Defense Advanced Research Projects Agency (DARPA)
Denka Seiken Company
Department of Health and Human Services (HHS)
DSM Biologics
DynPort
Eclipse Therapeutics
Eden Biodesign
Eurogentec Biologics
European Medicines Agency (EMA)
European Vaccine Manufacturers (EVM)
FDA (Food and Drug Administration), US
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
GAVI Alliance
GE Healthcare
GlaxoSmithKline (GSK)
Goodwin Biotechnology
Grand River Aseptic Manufacturing
Health and Human Services (HHS)
Health Canada
Hospira
HTD Biosystems
Hualan Biological Engineering
IDT Biologika
Immune Pharmaceuticals
Impfstoffwerk Dessau-Tornau (IDT)
Innogenetics Biologicals
Institute of Technology in Immuno-biologicals of the Oswaldo Cruz Foundation
Intercell
International AIDS Vaccine Initiative (IAVI)
IntroGene
Irvine Scientific
Johnson & Johnson (J&J)
Jubilant HollisterStier
Kalon Biotherapeutics
Kitasato Institute
Klocke
Korean FDA
Kuhner
Lonza
Medicago
MedImmune
Merck & Co.
Merck Millipore
Merck Serono
Meridian Bioscience
Meridian Life Science
Millipore
Ministry of Health, Labour and Welfare (Japan)
MP Biomedicals
Nascent Biologics
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH), US
NICE (National Institute for Health and Clinical Excellence), UK
Novartis
Novavax
OHSU
Organon Teknika Corporation
Pall Life Sciences
Pantec
Paragon Bioservices
Pasteur Merieux Serums & Vaccines
Patheon
PBS Biotech
Pfenex
Pfizer
PharmAthene
Pierre-Guérin Biolafitte
ProBioGen
Protein Sciences Corporation
Refine Technology
Research Foundation for Microbial Diseases of Osaka University
SAFC (Sigma-Aldrich Fine Chemicals)
Sanofi (formerly sanofi-aventis)
Sanofi Pasteur MSD
Sartorius Stedim Biotech
Serum Institute of India
Shantha Biotech
Sigma-Aldrich
Sinovac
Synco Bio Partners
Teva Pharmaceutical Industries
Thermo Fisher
Thermo Scientific
UNICEF
United Nations
Vibalogics
Vivalis
Vivante GMP Solutions
Vrije Universiteit
Waisman Biomanufacturing
Wave Biotech (now part of GE Healthcare Life Sciences)
World Health Organization (WHO)
Wyeth
Xcellerex
Xencor
Zhejiang Tianyuan

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.


SOURCE Visiongain



Mer från detta företag

Journalister och bloggare

Besök PR Newswire för journalister för utsläpp, foton och anpassas matar bara för Media.

Visa och hämta arkiverade video Innehållet distribueras av MultiVu på Den digitala Center.

Share with Twitter Share with LinkedIn
 

Skapa innehåll för din webbplats

Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
börja idag.

 

 
 
 

Kontakta PR Newswire

Skicka oss ett mail till stockholm@prnewswire.se eller ring oss på +46 (0)8 1200 1300

 

 
 
 

Bli en PR Newswire kund

Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300

 

 
 
  1. Produkter & tjänster
  2. Pressmeddelanden
  3. Kontakta PR Newswire